20.500.12556/DiRROS-28908 The safety of percutaneous renal biopsy for acute kidney injury in metastatic renal cell cancer patients with reduced nephron mass Background: Percutaneous renal biopsy (PRB) provides valuable information to guide treatment decisions in patients with metastatic renal cell carcinoma (mRCC) who develop acute kidney injury (AKI) after systemic anticancer therapy (SACT). The rising incidence of renal cell carcinoma (RCC) and the substantial impact of SACT on overall survival suggest a higher prevalence of RCC patients with reduced nephron mass and a solitary kidney (SK) requiring PRB for AKI. However, safety data on SK biopsies are scarce, and the potential for dialysis-requiring complications may deter clinicians. Methods: This retrospective case series reports the safety of 13 PRBs in 12 mRCC patients with reduced nephron mass who developed AKI during SACT as well as six PRBs in six patients with metastatic solid malignancies and AKI, which developed during SACT. Results: Eleven biopsies in mRCC patients and five biopsies in patients with metastatic solid malignancies were uneventful. One patient with mRCC experienced a major bleeding event due to an arteriovenous (AV) fistula seven days post-procedure, while another mRCC patient developed macrohematuria within 24 hours. In the group of patients with metastatic solid malignancies, one patient experienced a small perinephric hematoma during the observational period. Despite the small sample size, individual chart reviews and direct management of adverse events allowed assessment of the association between biopsy and complications. percutaneous renal biopsy renal cell cancer internal oncology perkutana ledvična biopsija rak ledvičnih celic internistična onkologija true false true Angleški jezik Slovenski jezik Neznano 2026-04-13 14:05:35 2026-04-13 14:05:36 2026-04-14 03:50:24 0000-00-00 00:00:00 2025 0 0 Nasl. z nasl. zaslona; Opis vira z dne 19. 8. 2025; str. 1615779-1-1615779-9 Vol. 5 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 2234-943X 10.3389/fneph.2025.1615779 246100995 RAZ_Milanez_Tomaz_2025.pdf RAZ_Milanez_Tomaz_2025.pdf 1 737DE3EC6FFAF3BDC8DD05A43E8B9A50 8073efc8f5ce8508e88b823537d9a986d2dd718819a50edf5b9180a3b036c4f2 ed12a495-3732-11f1-9cc3-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=43111 https://www.frontiersin.org/journals/nephrology/articles/10.3389/fneph.2025.1615779/full 1 159e2b91-3731-11f1-9cc3-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=43110 Univerzitetni klinični center Ljubljana 0 0 0